CRNX Stock Forecast 2025-2026
Distance to CRNX Price Targets
CRNX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Crinetics Pharma (CRNX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CRNX and similar high-potential opportunities.
Latest CRNX Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, CRNX has a bullish consensus with a median price target of $72.50 (ranging from $53.00 to $100.00). Currently trading at $34.90, the median forecast implies a 107.7% upside. This outlook is supported by 15 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRNX Analyst Ratings
CRNX Price Target Range
Latest CRNX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRNX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2025 | Stifel | Alex Thompson | Buy | Initiates | $60.00 |
| Feb 28, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Maintains | $91.00 |
| Feb 4, 2025 | Wolfe Research | Andy Chen | Peer Perform | Initiates | $0.00 |
| Jan 22, 2025 | Jefferies | Dennis Ding | Buy | Upgrade | $55.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $81.00 |
| Dec 16, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $87.00 |
| Nov 14, 2024 | Citigroup | David Lebovitz | Buy | Maintains | $74.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $81.00 |
| Sep 27, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $80.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $90.00 |
| Aug 9, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $73.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $69.00 |
| Jul 9, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $54.00 |
| Jul 2, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $97.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $60.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $60.00 |
| Jun 4, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $80.00 |
| Jun 4, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $74.00 |
| May 23, 2024 | Baird | Brian Skorney | Outperform | Maintains | $62.00 |
| May 23, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $60.00 |
Crinetics Pharmaceuticals Inc. (CRNX) Competitors
The following stocks are similar to Crinetics Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Crinetics Pharmaceuticals Inc. (CRNX) Financial Data
Crinetics Pharmaceuticals Inc. has a market capitalization of $3.21B with a P/E ratio of -9.5x. The company generates $1.04M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -32,613.5% and return on equity of -32.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Crinetics Pharmaceuticals Inc. (CRNX) Business Model
About Crinetics Pharmaceuticals Inc.
Develops novel therapeutics for endocrine conditions.
Crinetics Pharmaceuticals operates by developing and commercializing oral therapies targeting hormone receptors for endocrine disorders and rare diseases. The company generates revenue through the advancement of its investigational drugs, which are aimed at treating conditions such as acromegaly and congenital adrenal hyperplasia.
Based in San Diego, California, Crinetics collaborates with academic institutions and industry partners to drive innovation in drug discovery. The company focuses on small molecules to create new treatment options that address significant unmet medical needs, positioning itself to impact the pharmaceutical industry positively.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
437
CEO
Dr. R. Scott Struthers Ph.D.
Country
United States
IPO Year
2018
Website
www.crinetics.comCrinetics Pharmaceuticals Inc. (CRNX) Latest News & Analysis
Crinetics Pharmaceuticals' paltusotine has had its MAA validated by the EMA for acromegaly treatment. It also received Orphan Drug Designation in February 2025.
Crinetics’ paltusotine gaining EMA validation and Orphan Drug Designation boosts its market potential, enhancing investor confidence in future revenue and stock performance.
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 days agoCrinetics Pharmaceuticals granted stock options for 95,675 shares and RSUs for 40,775 shares to new non-executive employees, plus additional awards to one executive, as per the 2021 Inducement Plan.
The stock option and RSU grants indicate Crinetics' commitment to attract talent, potentially enhancing innovation and growth, which can positively influence stock performance.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) will hold its Q4 2024 results conference call on February 27, 2025, at 4:30 PM ET, featuring key executives and analysts.
The Q4 2024 results call indicates upcoming financial performance insights and strategic direction from Crinetics Pharmaceuticals, impacting stock valuation and investor sentiment.
Crinetics Pharmaceuticals is on track for its September 25, 2025 PDUFA date, planning four late-stage trials and maintaining a strong financial position with $1.4B cash. Conference call at 4:30 p.m. ET today.
Crinetics Pharmaceuticals is on track for key regulatory milestones and trials, indicating growth potential. Strong cash reserves enhance stability, appealing to investors focused on future developments.
Crinetics Pharmaceuticals appointed Tobin Schilke as CFO, effective February 28, 2025. He brings over 25 years of experience in the biopharma sector.
The appointment of a seasoned CFO like Tobin Schilke could indicate strategic financial management and stability for Crinetics Pharmaceuticals, potentially influencing investor confidence and stock performance.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in the TD Cowen Healthcare Conference in Boston and the Leerink Global Healthcare Conference in Miami.
Crinetics Pharmaceuticals' participation in major investment conferences signals potential interest from analysts and investors, which could influence stock performance and market perception.
Frequently Asked Questions About CRNX Stock
What is Crinetics Pharmaceuticals Inc.'s (CRNX) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Crinetics Pharmaceuticals Inc. (CRNX) has a median price target of $72.50. The highest price target is $100.00 and the lowest is $53.00.
Is CRNX stock a good investment in 2025?
According to current analyst ratings, CRNX has 15 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRNX stock?
Wall Street analysts predict CRNX stock could reach $72.50 in the next 12 months. This represents a 107.7% increase from the current price of $34.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Crinetics Pharmaceuticals Inc.'s business model?
Crinetics Pharmaceuticals operates by developing and commercializing oral therapies targeting hormone receptors for endocrine disorders and rare diseases. The company generates revenue through the advancement of its investigational drugs, which are aimed at treating conditions such as acromegaly and congenital adrenal hyperplasia.
What is the highest forecasted price for CRNX Crinetics Pharmaceuticals Inc.?
The highest price target for CRNX is $100.00 from at , which represents a 186.5% increase from the current price of $34.90.
What is the lowest forecasted price for CRNX Crinetics Pharmaceuticals Inc.?
The lowest price target for CRNX is $53.00 from at , which represents a 51.9% increase from the current price of $34.90.
What is the overall CRNX consensus from analysts for Crinetics Pharmaceuticals Inc.?
The overall analyst consensus for CRNX is bullish. Out of 17 Wall Street analysts, 15 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $72.50.
How accurate are CRNX stock price projections?
Stock price projections, including those for Crinetics Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
